BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20824479)

  • 21. The odyssey of marine pharmaceuticals: a current pipeline perspective.
    Mayer AM; Glaser KB; Cuevas C; Jacobs RS; Kem W; Little RD; McIntosh JM; Newman DJ; Potts BC; Shuster DE
    Trends Pharmacol Sci; 2010 Jun; 31(6):255-65. PubMed ID: 20363514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving drug discovery with contextual assays and cellular systems analysis.
    Westwick JK; Lamerdin JE
    Methods Mol Biol; 2011; 756():61-73. PubMed ID: 21870220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug safety sciences and the bottleneck in drug development.
    Watkins PB
    Clin Pharmacol Ther; 2011 Jun; 89(6):788-90. PubMed ID: 21593756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of smoking cessation drugs by the Food and Drug Administration.
    Richins C
    Food Drug Law J; 2009; 64(2):277-90. PubMed ID: 19999284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of how drugs are designed and developed.
    Gallimore D
    Nurs Times; 2006 Nov 21-27; 102(47):30-1. PubMed ID: 17153043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network systems biology for drug discovery.
    Arrell DK; Terzic A
    Clin Pharmacol Ther; 2010 Jul; 88(1):120-5. PubMed ID: 20520604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [System biology and synthetic biology modify drug discovery and development].
    Haiech J; Ranjeva R; Kilhoffer MC
    Med Sci (Paris); 2012 Feb; 28(2):207-12. PubMed ID: 22377310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational bioinformatics in psychoneuroimmunology: methods and applications.
    Yan Q
    Methods Mol Biol; 2012; 934():383-400. PubMed ID: 22933157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational bioinformatics and systems biology approaches for personalized medicine.
    Yan Q
    Methods Mol Biol; 2010; 662():167-78. PubMed ID: 20824471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is next for small-molecule drug discovery?
    Doweyko AM; Doweyko LM
    Future Med Chem; 2009 Sep; 1(6):1029-36. PubMed ID: 21425992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug profiling: knowing where it hits.
    Merino A; Bronowska AK; Jackson DB; Cahill DJ
    Drug Discov Today; 2010 Sep; 15(17-18):749-56. PubMed ID: 20601095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Network biology as a new approach to drug discovery.
    Lowe JA; Jones P; Wilson DM
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):524-6. PubMed ID: 20812143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 40. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.